Searched for
DR ARVIND LAL
JioBlackRock Flexi Cap Fund exits Adani Enterprises, Adani Ports and 3 other companies; adds Tata Motors and 14 more stocksJioBlackRock Flexi Cap Fund exited Adani Enterprises, Adani Ports and three other stocks in May while adding Tata Motors and 14 new stocks ...- Sunil Singhania-backed Abakkus Small Cap Fund adds 3 new stocks, increases stake in HDFC Bank, SBI and 49 othersSunil Singhania's Abakkus Small Cap Fund added three new stocks in May, including Tanla Platforms and Intellect Design Arena. The fund also...
- Add Dr Lal Pathlabs, target price Rs 2,910: HDFC SecuritiesHDFC Securities has an 'add' call on Dr Lal Pathlabs with a target price of Rs 2910. The company reported a total income of Rs 621.80 crore...
- Dr Lal PathLabs sets sights on big buys to expand in south"In south, we are open to looking at M&A opportunities, we did (acquisition of) Suburban (Diagnostics in the Western region). It was our fi...
- Reduce Dr. Lal Pathlabs, target price Rs 1875: Yes SecuritiesReduce Dr. Lal Pathlabs at a price target of Rs 1875.
- Buy Dr. Lal Pathlabs, target price Rs 2620: JM FinancialDr. Lal Pathlabs, incorporated in the year 1995, is a Mid Cap company (having a market cap of Rs 15012.92 Crore) operating in Hospitals & A...
- Buy Dr. Lal Pathlabs, target price Rs 2820: BNP Paribas SecuritiesPromoters held 55.05 per cent stake in the company as of 30-Sep-2022, while FIIs owned 22.37 per cent, DIIs 6.27 per cent.
- Dr Lal PathLabs to ramp up operations in Western India"The new reference lab provides a wide array of super-specialised, specialised and routine diagnostic tests for meeting all diagnostic need...
- Dr Lal PathLabs Q2 results: Net profit up 7.5% to Rs 87 crRevenue from operations stood at Rs 431.9 crore for the quarter under consideration. It was Rs 365.6 crore for the same period a year ago, ...
- Dr Lal PathLabs Q1 results: Net profit declines 52% to Rs 28.4 croreThe company had posted a net profit of Rs 59.1 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing ...
- Dr Lal PathLabs Q4 results: Net profit declines 31% to Rs 32.6 croreThe company had posted a net profit of Rs 47.4 crore for the corresponding period of previous fiscal.
- Buy Dr. Lal Pathlabs, target Rs 1,249: Dharmesh ShahBuy Dr. Lal Pathlabs Ltd. at a price target of Rs 1249.0 and a stoploss at Rs 1136 from entry point.
- Buy Dr Lal Pathlabs, target Rs 1,235: Dharmesh ShahBuy Dr. Lal Pathlabs Ltd. at a price target of Rs 1235.0 and a stoploss at Rs 1148 from entry point.
- Dr Lal PathLabs: Sweet pill in Dec quarter, expansion key to future growthThe main concern should be the company’s excessive concentration on the North market.
- Buy Dr. Lal Pathlabs, target Rs 900: Edelweiss Financial ServicesBuy Dr. Lal Pathlabs at a price target of Rs 900. Time period given by analyst is a year when Dr. Lal Pathlabs price can reach defined targ...
- Dr Lal PathLabs Q3 profit more than doubles to Rs 61 croreDr Lal PathLabs today reported over two-fold jump in consolidated net profit at Rs 60.82 crore for the third quarter ended December 31, 201...
- Sequoia to sell around 15% in PathLabsSequoia Capital has put a part of its 30% stake in one of the country’s largest diagnostics and pathology services chain, Dr Lal PathLabs, ...
- US check-ups on Indian shoresMedical diagnostics major Dr Lal PathLabs may soon be the first Indian company to conduct diagnostic tests of patients in the US.
- Dr Lal Pathlabs to expand, hit marketsPathology chain, Dr Lal Pathlabs on Tuesday announced its expansion strategy, besides its plans to hit the capital market over the next 2-3...
- Dr Lal PathLabs to set up 30 new labsMedical diagnostic services provider, Dr Lal PathLabs, is planning to more than double its pathological laboratories in the country, as it ...
Load More
